223 related articles for article (PubMed ID: 30945387)
1. The utilization and challenges of Japan's MID-NET
Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
[TBL] [Abstract][Full Text] [Related]
2. Establishment of the MID-NET
Yamaguchi M; Inomata S; Harada S; Matsuzaki Y; Kawaguchi M; Ujibe M; Kishiba M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Takahashi F; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Oct; 28(10):1395-1404. PubMed ID: 31464008
[TBL] [Abstract][Full Text] [Related]
3. Use of National Database of Health Insurance Claims and Specific Health Checkups for examining practical utilization and safety signal of a drug to support regulatory assessment on postmarketing drug safety in Japan.
Shida H; Kajiyama K; Sawada S; Ishiguro C; Kubo M; Kimura R; Hirano M; Komiyama N; Iguchi T; Oniyama Y; Uyama Y
Front Med (Lausanne); 2023; 10():1096992. PubMed ID: 36910503
[TBL] [Abstract][Full Text] [Related]
4. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
5. Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
[TBL] [Abstract][Full Text] [Related]
6. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
7. [From a Viewpoint of Clinical Settings: Pharmacoepidemiology as Reverse Translational Research (rTR)].
Kawakami J
Yakugaku Zasshi; 2017; 137(6):681-683. PubMed ID: 28566573
[TBL] [Abstract][Full Text] [Related]
8. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.
Yang Y; Zhou X; Gao S; Lin H; Xie Y; Feng Y; Huang K; Zhan S
Drug Saf; 2018 Jan; 41(1):125-137. PubMed ID: 28815480
[TBL] [Abstract][Full Text] [Related]
10. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
Ishiguro C; Misu T; Iwasa E; Izawa T
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
[TBL] [Abstract][Full Text] [Related]
11. The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan.
Ishiguro C; Takeuchi Y; Uyama Y; Tawaragi T
Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):854-9. PubMed ID: 27222073
[No Abstract] [Full Text] [Related]
12. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
13. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.
Strom BL
Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576
[TBL] [Abstract][Full Text] [Related]
14. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
[TBL] [Abstract][Full Text] [Related]
15. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
[TBL] [Abstract][Full Text] [Related]
16. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.
Pacurariu A; Plueschke K; McGettigan P; Morales DR; Slattery J; Vogl D; Goedecke T; Kurz X; Cave A
BMJ Open; 2018 Sep; 8(9):e023090. PubMed ID: 30185579
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
[TBL] [Abstract][Full Text] [Related]
18. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance: Importance, concepts, and processes.
Kumar A
Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
[No Abstract] [Full Text] [Related]
20. [Making Patient-focused Information Provision a Reality: One Company's Approach].
Takemoto S
Yakugaku Zasshi; 2018; 138(3):315-323. PubMed ID: 29503422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
